AZD5055

AZD5055 (formerly known as RXC006) is a potent, selective, orally available small molecule inhibitor of the enzyme Porcupine (PORCN), a key activator of Wnt ligands in the Wnt signaling pathway. By inhibiting Porcupine, AZD5055 blocks the palmitoylation and release of Wnt proteins such as Wnt3A and Wnt5A. This leads to inhibition of downstream Wnt signaling implicated in fibrotic processes. Preclinical studies have demonstrated anti-fibrotic effects in models of kidney, liver, and lung fibrosis. The drug is being developed primarily for idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs). Originally discovered by Redx Pharma as RXC006 and later licensed to AstraZeneca for clinical development[1][2][6][7].